Relationship Between Self-compassion and Treatment Adherence in Schizophrenic Spectrum Disorders

NCT05566015 | Withdrawn

• 1 other identifier: PI2019_843_0021
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Treatment adherence is defined by the World Health Organisation (WHO) as the extent to which the patient's history of therapeutic drug-taking coincides with the prescribed treatment. In patients suffering from psychiatrical diseases, especially in those who are suffering from schizophrenic spectrum disorders, the quality of treatment adherence has to be improved. Indeed, non adherance to anti-psychotic treatment increases the risk of hospitalization, of substance use, violent behaviour and of functionnal and cognitif impairment. Selfcompassion, which involves being touched by and open to one's own suffering and to heal oneself with kindness and without judgement and self-criticism has never beed studied as a possible factor infuencing treatment adherence. This study aims to evaluate if a link between selfcompassion and treatment adherence exists in patients suffering from schizophrenic spectrum disorders.

Conditions

Treatment Adherence; Selfcompassion; Schizophrenic Spectrum Disorder

Keywords

Treatment Adherence; Selfcompassion; schizophrenic spectrum disorder

Outcome Measures

Primary Outcomes (1)

• Average level of self compassion

  The level of self compassion will be assessed with the french version of the Self-compassion scale developped and tested by K.Neff. Average scores for the Self-Compassion Scale are around 3.0 on the 1-5 Likert scale, a score of 1-2.5 indicates low self-compassion, 2.5-3.5 indicates moderate, and 3.5-5.0 is an indication of high self-compassion

  one hour

Interventions

questionnaire OTHER

self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• patients diagnosed with schizophrenia spectrum disorder ( ICD 10 and DSM 5 criteria)
• stabilized (PANNS score under 80)
• aged 18 or above
• In case of tutor or curator, agreement of this person is requiered
• psychiatrist who's following the patient agrees with the study

You may not qualify if:

• underage
• non stabilized patient (PANSS score under 80 )
• patient suffering from toxic psychosis
• difficulties to understand french or cognitive impairment which are making it to difficult to answer the different self-administered questionnaires.

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead
• Crysalid center Clermont de l'Oise: collaborator
• CMP de Montataire: collaborator
• CMP de Chambly: collaborator
• CMP de Clermont de l'Oise: collaborator
• CMP de st Just en Chaussée: collaborator
• CMP de Senlis: collaborator
• CMP de Crepy en Valois: collaborator
• CMP de Pont St Maxence: collaborator
• CMP de Chantilly: collaborator
• CMP de Creil: collaborator

Study Sites (1)

CHU Amiens

Amiens, 80480, France

Location

MeSH Terms

Conditions

Treatment Adherence and Compliance

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Health Behavior; Behavior

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 30, 2022
• First Posted: October 4, 2022
• Study Start: September 26, 2022
• Primary Completion: July 1, 2023
• Study Completion: July 1, 2023
• Last Updated: July 20, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)